Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8NET8
UPID:
TRPV3_HUMAN
Alternative names:
Vanilloid receptor-like 3
Alternative UPACC:
Q8NET8; Q8NDW7; Q8NET9; Q8NFH2
Background:
Transient receptor potential cation channel subfamily V member 3 (TRPV3), also known as Vanilloid receptor-like 3, plays a pivotal role in temperature sensation and hair growth regulation. It functions as a putative receptor-activated non-selective calcium permeant cation channel, responsive to warm temperatures and showing increased activity at noxious temperatures above 39 degrees Celsius. TRPV3's interaction with TRPV1 modulates its activity, highlighting its integral role in sensory perception.
Therapeutic significance:
TRPV3's involvement in Olmsted syndrome 1 and non-epidermolytic, focal palmoplantar keratoderma 2 underscores its therapeutic potential. Targeting TRPV3 could lead to innovative treatments for these dermatological disorders, offering hope for patients suffering from these debilitating conditions.